Business Wire

OH-PROCTER-&-GAMBLE

14.5.2024 14:01:28 CEST | Business Wire | Press release

Share
P&G unveils plans to prominently feature superior performing brands during the Olympic and Paralympic Games Paris 2024

Procter & Gamble (NYSE: PG), a Worldwide Olympic and Paralympic Partner, announced plans today to prominently feature superior performing household and personal care brands during the Olympic and Paralympic Games Paris 2024 including Olympic-inspired brand marketing and in-store campaigns, brand-sponsored athlete partnerships, and complimentary products and services for athletes in the Athletes’ Village during Paris 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514255957/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Village Nursery with Pampers (Photo: Business Wire)

Before and during Paris 2024, more than 30 P&G brands will reach billions of engaged consumers in countries around the world through relevant ways that demonstrate product performance superiority. Inspired by the highest performance of the best athletes in the world, P&G’s household and personal care brands are launching Olympic and Paralympic Games-inspired marketing campaigns featuring the highest performance products that serve people every day, including:

  • Pampers empowers little champions on the move with Pampers® NEW Baby-Dry™ Pants, providing a superior fit and protection to win against leaks.
  • Ariel’s “Champion of Stain and Odor Removal” campaign is taking care of clothes on and off the field, even in cold and short washing machine cycles which are the toughest cleaning conditions.
  • Fairy’sTough Stain Cleaning Champion” campaign features its mascot, Mr. Fairy, and demonstrates superior product performance in automatic dishwashers, even in short cycles.
  • Venus is launching “The Power of Smooth” campaign to highlight Venus as the razor athletes trust to achieve smooth skin, especially in the last step in their pre-competition routine.
  • Gillette, a brand with a strong sports heritage, is bringing to life its long-standing promise of "the best a man can get" through a gold razor for Paris 2024 and a campaign featuring its highest performing Gillette Labs product line.
  • Always is the Official Period Product of Paris 2024. The “It's a New Period” campaign is aimed at addressing and eliminating period anxiety in the world of sports through the power of products with superior protection.
  • Head & Shoulders “Gold Medal Against Dandruff” features the “I Don’t” campaign, demonstrating how the brand prevents dandruff with an Olympic Games-themed twist.
  • Oral-B’s “Brush Like a Champion” campaign leverages the brand's role as the Official Oral Care Products of Paris 2024 to promote the use of Oral-B for cleaner, stronger teeth.
  • ZzzQuil’s “Sleep Like an Everyday Champion” campaign promotes better sleep as the key to performing at your best.

“Every day, P&G brands provide consumers with high performance products that they trust to meet their daily household and personal care needs for themselves and their families,” said P&G Chief Brand Officer Marc Pritchard. “That inspired us to prominently feature how those superior performing products serve athletes, families and fans so they can focus on achieving their personal best whether on the Olympic or Paralympic stage or in those everyday moments in life that matter.”

These P&G brand marketing campaigns and more will be supported by in-store and online retail activations across more than 150 retailers in more than 40 countries around the world. Over the last several Games, P&G and retailers have worked together to develop the Olympic and Paralympic Games into a highly relevant platform for engaging consumers to drive growth and value creation. The Games are particularly relevant in the host region and for Paris 2024, P&G brands are activating in retail stores across Europe behind the “Everyday Champions” campaign, providing products that give their best every day to meet the household and personal care needs of athletes, families, and fans – just like Olympians and Paralympians give their best to their sport.

During the Games, P&G brands will be providing more complimentary services and products to athletes than ever before, so they can focus on achieving their best when they step out on the world’s biggest stage. P&G brands will meet the everyday demands of more than 22,000 athletes and their staff within the Athletes’ Village, offering accessible and inclusive products and services, including:

  • The Village Nursery with Pampers: For the first time in the Olympic and Paralympic Games, Pampers® is creating a comfortable and convenient environment for athlete parents to connect with their babies and young children to enjoy precious moments together in the Athletes’ Village during Paris 2024. The nursery will provide a space for playtime and family bonding and cater to all babies and their diapering needs with Pampers highest quality diapers and wipes.
  • Beauty & Grooming Salon by Pantene®, Head & Shoulders®, Mielle®, Gillette® and Braun® will provide complimentary beauty and grooming treatments designed for all athletes to help them look and feel their best so they focus on giving their best when it matters most.
  • Laundry Rooms supplied by Ariel: Athletes will experience outstanding cleaning performance when they bring their clothes and uniforms to the laundry rooms for cold water washing laundry services supplied by Ariel, the Official Laundry Product of Paris 2024.
  • Dental Clinic with Oral-B® will give athletes the confidence of healthy smiles, offering athletes access to general and emergency dental services with high-performance Oral-B® toothbrushes, toothpastes and oral care education.
  • Period Protection: Always and Tampax® will provide period protection products in the restrooms throughout the Athletes’ Village.
  • P&G Everyday Champions Welcome Kit: Each athlete will receive a Paris-themed reusable bag equipped with P&G brand products such as Oral-B, Head & Shoulders, Aussie, Safeguard and Febreze to support their health and hygiene needs during Paris 2024.

“It’s incredible to see P&G brands recognize what matters most to athletes and show up for them during the Olympic and Paralympic Games in meaningful ways,” said Dame Laura Kenny, six-time Olympic medalist. “For athletes who are also juggling their role as a parent, connecting with their babies in an accessible space like the Village Nursery with Pampers will be an amazing resource, providing such valuable support to Olympic and Paralympic athletes during Games Time.”

P&G and P&G brands are also partnering with more than 100 of the world’s top-performing athletes, supporting their endeavors on and off the field of play in a variety of ways, through financial resources and even grant funding to their preferred charities through the Athletes for Good program. P&G’s full roster of athletes represents 17 countries and 37 sports and includes:

  • Two-time Olympic Gold Medalist Clarisse Agbegnenou, Judo, France, partnering with Pampers, Ariel, and Oral-B;
  • Olympic Gold Medalist Niek Kimmann, BMX, Netherlands, partnering with Gillette;
  • Three-time Paralympic Gold Medalist Marie-Amélie Le Fur, Para athletics, France, partnering with Always;
  • Paralympic Gold Medalist Alexis Hanquinquant, Para triathlon, France, partnering with Braun, Gillette, Head & Shoulders, and Oral-B;
  • Paralympic Gold Medalist Anastasia Pagonis, Para swimming, USA, partnering with Venus;
  • Two-time Olympic Medalist, Lydia Jacoby, Swimming, USA, partnering with Venus;
  • Olympic Gold Medalist Wang Shun, Swimming, China, partnering with Safeguard.

About P&G’s Olympic & Paralympic Games Program

P&G has been a Worldwide Partner of the International Olympic Committee (IOC) since 2010. In July 2020, P&G announced the extension of its worldwide partnership with the Olympic Games through the LA28 Games, including global rights with the International Paralympic Committee (IPC) and the Paralympic Games. Since becoming a Worldwide Partner of the Olympic Games, the Company and its brands including Always®, Tide®, Ariel®, Gillette® and Head & Shoulders® have partnered with more than 500 athletes to shine a light on their daily commitment to be the best they can be, just as P&G brands commit to delivering superior performance for people who count on the brands in their everyday lives.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at https://www.pg.com/news.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514255957/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye